Bevacizumab for malignant pleural effusion in ovarian clear cell carcinoma: a case report

IF 0.5 4区 医学 Q4 OBSTETRICS & GYNECOLOGY European journal of gynaecological oncology Pub Date : 2021-06-15 DOI:10.31083/J.EJGO.2021.03.2338
Di Wu, Yanqin Zhang, Jinwei Miao
{"title":"Bevacizumab for malignant pleural effusion in ovarian clear cell carcinoma: a case report","authors":"Di Wu, Yanqin Zhang, Jinwei Miao","doi":"10.31083/J.EJGO.2021.03.2338","DOIUrl":null,"url":null,"abstract":"Objective: Malignant pleural effusion (MPE) is a major problem associated with late phase of epithelial ovarian cancer for which an optimum treatment consensus has yet to be determined. Although bevacizumab (Bev), a VEGF ligand inhibitor, has been shown to effectively control MPE, the clinical benefit of half-dose Bev treatment to control MPE remains unclear. Methods: We describe a patient with platinum-sensitive ovarian clear cell cancer (OCCC) and symptomatic MPE for whom tumor markers increased after one cycle of paclitaxel and carboplatin chemotherapy. After switching to five cycles of Bev plus paclitaxel/carboplatin chemotherapy, we observed the disappearance of MPE. Conclusion: The half-dose Bev therapy may be an effective treatment for MPE in OCCC. However, further investigation is still warranted to evaluate the therapeutic effectiveness of Bev.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"42 1","pages":"587-589"},"PeriodicalIF":0.5000,"publicationDate":"2021-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of gynaecological oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/J.EJGO.2021.03.2338","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Objective: Malignant pleural effusion (MPE) is a major problem associated with late phase of epithelial ovarian cancer for which an optimum treatment consensus has yet to be determined. Although bevacizumab (Bev), a VEGF ligand inhibitor, has been shown to effectively control MPE, the clinical benefit of half-dose Bev treatment to control MPE remains unclear. Methods: We describe a patient with platinum-sensitive ovarian clear cell cancer (OCCC) and symptomatic MPE for whom tumor markers increased after one cycle of paclitaxel and carboplatin chemotherapy. After switching to five cycles of Bev plus paclitaxel/carboplatin chemotherapy, we observed the disappearance of MPE. Conclusion: The half-dose Bev therapy may be an effective treatment for MPE in OCCC. However, further investigation is still warranted to evaluate the therapeutic effectiveness of Bev.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
贝伐单抗治疗卵巢透明细胞癌恶性胸腔积液1例
目的:恶性胸腔积液(MPE)是与晚期上皮性卵巢癌相关的主要问题,其最佳治疗共识尚未确定。尽管VEGF配体抑制剂贝伐单抗(bevacizumab, Bev)已被证明能有效控制MPE,但半剂量Bev治疗控制MPE的临床益处尚不清楚。方法:我们描述了一个铂敏感卵巢透明细胞癌(OCCC)和症状性MPE患者,其肿瘤标志物在紫杉醇和卡铂化疗一个周期后升高。切换到5个周期的Bev +紫杉醇/卡铂化疗后,我们观察到MPE消失。结论:半剂量贝弗可能是治疗OCCC MPE的有效方法。然而,Bev的治疗效果仍有待进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
25.00%
发文量
58
审稿时长
1 months
期刊介绍: EJGO is dedicated to publishing editorial articles in the Distinguished Expert Series and original research papers, case reports, letters to the Editor, book reviews, and newsletters. The Journal was founded in 1980 the second gynaecologic oncology hyperspecialization Journal in the world. Its aim is the diffusion of scientific, clinical and practical progress, and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists, and so on.
期刊最新文献
Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study. Vulvar cancer in young woman—case report Identification of an immune-related metabolic gene signature to predict possible prognosis in endometrial cancer and reveals immune landscape feature Evaluation of colposcopy and LEEP results performed in gynecology and gynecological oncology surgery services The infrequent large pelvi-perineal tumors as a surgical dilemma: en bloc resection and long-term results
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1